Physician profile
Ian Walker
NPI 1609261726
$10,263.27
in general payments reported to CMS, 2019-2025
24 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $585 · 2021: $98.37 · 2022: $3,051 · 2023: $2,473 · 2024: $2,491 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,972 · Food and Beverage: $2,248 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,972.36 |
| Food and Beverage | $2,248.00 |
| Education | $121.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,444.83 | 2023-2025 | Infinity, Proclaim |
| Abbvie INC. | $2,118.18 | 2022-2025 | |
| Boston Scientific Corporation | $1,595.36 | 2022-2025 | General - Dbs |
| Medtronic USA, INC. | $772.64 | 2019-2020 | |
| Medtronic, INC. | $311.50 | 2021-2025 | Percept PC Brainsense, Activa PC |
| Acadia Pharmaceuticals INC | $190.86 | 2024-2025 | Nuplazid |
| Ucb, INC. | $158.18 | 2023-2025 | Rystiggo, Fintepla, Zilbrysq |
| Neurocrine Biosciences, INC. | $156.71 | 2024-2025 | Ingrezza |
| Mdd US Operations, LLC | $105.63 | 2025 | Gocovri |
| Teva Pharmaceuticals USA, INC. | $78.94 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Sk Life Science, INC. | $64.61 | 2024-2025 | |
| Biogen, INC. | $40.88 | 2025 | Vumerity, Tysabri |
| Lundbeck LLC | $33.39 | 2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $32.77 | 2024-2025 | Crexont, Ongentys |
| Pfizer INC. | $21.26 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $20.00 | 2024 | Hizentra |
| Merz Pharmaceuticals, LLC | $19.96 | 2025 | Inbrija |
| Genentech USA, INC. | $18.68 | 2025 | Ocrevus Zunovo |
| Neurelis, INC. | $17.06 | 2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $16.63 | 2024 | Ponvory |
| Alexion Pharmaceuticals, INC. | $15.27 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $14.96 | 2024 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $13.33 | 2024 | Dysport |
| Supernus Pharmaceuticals, INC. | $1.64 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.